STOCK TITAN

United-Guardian (UG) Stock Price, News & Analysis

UG NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
13 251 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+31.9% close of November 9, 2026
1-year change
+26.7% closing prices, November 20, 2025 to November 20, 2026
1-month change
+8.7% closing prices, October 20, 2026 to November 20, 2026

Company Description

United-Guardian, Inc. (NASDAQ: UG) is a manufacturing company that focuses on specialty chemical products for personal care, healthcare, and related applications. According to the company’s public statements, United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. These activities place the company within the "All Other Miscellaneous Chemical Product and Preparation Manufacturing" industry in the broader manufacturing sector.

United-Guardian states that it operates through a single business segment, with its product lines organized into four main categories: cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. Its product portfolio, as described in available materials, includes items such as Klensoft, Deselex, Renacidin, and Lubrajel Fluid. Renacidin is described by the company as its most important pharmaceutical product, and several of its public communications discuss efforts to increase Renacidin sales by expanding its inclusion on drug formularies.

Business focus and product categories

The company’s business is centered on the development, manufacture, and marketing of specialized chemical-based products. United-Guardian reports that its cosmetic ingredients are an important part of its operations, and that it has a growing line of natural cosmetic ingredients developed through its research and development activities. It also emphasizes pharmaceutical products, with Renacidin highlighted as a key product, and medical lubricants and sexual wellness ingredients as additional product categories.

According to prior descriptions, United-Guardian’s pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. The company has also indicated that its medical and specialty industrial products are sold directly to end-users or, in some cases, to contract manufacturers used by those end users. United-Guardian has stated that it derives key revenue from sales made in the U.S.

Manufacturing, distribution, and marketing relationships

United-Guardian’s public disclosures highlight the role of distribution and marketing partners in its business model. The company has repeatedly referenced Ashland Specialty Ingredients (ASI) as its largest cosmetic distributor and marketing partner for cosmetic ingredients. Company press releases explain that changes in ASI’s ordering patterns and inventory levels, particularly related to demand in Asia, have had a meaningful impact on United-Guardian’s cosmetic ingredient sales in certain periods. The company has also described ASI as a key channel for reaching customers for its cosmetic ingredients.

For its pharmaceutical and medical lubricant products, United-Guardian has discussed working with contract manufacturers and wholesalers. In its communications, the company has noted that a supply disruption at its contract manufacturer for Renacidin affected pharmaceutical sales during a prior period, and that sales began to recover as production resumed. It has also mentioned demand from contract manufacturer customers for its medical lubricants.

Research and development

United-Guardian reports ongoing research and development (R&D) activity, which is reflected as a separate expense line in its financial statements. The company has highlighted the role of R&D in developing new products, including a growing line of natural cosmetic ingredients. In its description of management experience, United-Guardian has noted that its internal R&D and microbiology functions have been central to product development and to expanding its personal care product offerings.

Dividend history and capital allocation

In multiple announcements, United-Guardian has emphasized a long history of paying cash dividends. The company has stated that it has paid a dividend for several decades in a row, and specific press releases describe cash dividends declared by its Board of Directors. United-Guardian has indicated that, when considering dividends, the Board evaluates both the desire to return cash to stockholders and the need to retain earnings to fund growth initiatives, including projects to expand the market for its personal care products and to increase sales of Renacidin.

Growth initiatives and strategic focus

United-Guardian’s public statements describe several ongoing initiatives. These include:

  • Projects to have Renacidin included on additional drug formularies, which the company believes could significantly increase sales of this product over time.
  • New strategies to grow the market for its personal care and cosmetic ingredients, including changes in global marketing and distribution of cosmetic ingredients.
  • Renewed emphasis on increasing sales of medical lubricants and pharmaceutical products.

In its commentary, United-Guardian has also discussed external factors that affect its business, such as tariff announcements on imports from various countries and demand conditions in Asia that influence orders from its largest cosmetic distributor. The company has noted that these factors can lead to changes in distributor inventory levels and order timing, which in turn impact its reported sales of cosmetic ingredients.

Stock listing and regulatory reporting

United-Guardian’s common stock trades on NASDAQ under the ticker symbol UG. The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports. Recent Form 8-K filings have been used to furnish press releases related to quarterly results and dividend declarations under the "Results of Operations and Financial Condition" and "Regulation FD Disclosure" items.

Geographic and industry context

Based on its industry classification, United-Guardian operates in the All Other Miscellaneous Chemical Product and Preparation Manufacturing category within the manufacturing sector. Its public communications indicate that it focuses on specialty products used in cosmetics, pharmaceuticals, medical lubrication, and sexual wellness applications. The company has highlighted the importance of demand trends in markets served by its distributors and contract manufacturers, including demand in Asia as reported by its largest cosmetic distributor.

Key product references

Across its descriptions and financial communications, United-Guardian has identified several specific products and product lines, including:

  • Renacidin (Renacidin Irrigation Solution), described as its most important pharmaceutical product.
  • Klensoft, Deselex, and Lubrajel Fluid, which are listed as part of its product portfolio.
  • A growing line of natural cosmetic ingredients, developed through its R&D efforts.

These products are grouped within the company’s four main categories of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients, which together form the core of United-Guardian’s business as described in its public materials.

Investor considerations

Investors researching United-Guardian (UG) can review the company’s press releases for commentary on sales trends by product category, the impact of distributor ordering patterns, and updates on projects related to Renacidin and personal care products. SEC filings provide additional detail on financial performance, costs and expenses, research and development spending, and other income such as investment income and gains or losses on marketable securities. Together, these sources outline how United-Guardian positions itself within the specialty chemical manufacturing space and how it describes the drivers of its business performance.

Stock Performance

$7.20
-2.04%
-0.15
After hoursChange vs the $7.35 closeLast updated: at
+26.7%
Performance 1 year
$33.1M
4.6M
Shares outstanding As of November 2, 2026.

United-Guardian (UG) closed at $7.35 on November 20, 2026. Over the past 12 months, the price has gained 26.7%.

See what a $1,000 investment in UG would be worth today

Average down calculator for UG

UG Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

United-Guardian has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, dividends, management. View all UG news →

Financial Highlights

United-Guardian generated $10.5M in revenue in FY2025, retaining a 48.8% gross margin, operating income reached $2.2M (21.3% operating margin), and net income was $2.1M, reflecting a 20.0% net profit margin. The company generated $2.0M in operating cash flow. The current ratio was 7.31, measuring current assets divided by current liabilities.

$10.5M
Revenue (FY2025)
$2.1M
Net Income (FY2025)
$2.0M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Product

Personal care product launch

United-Guardian plans a personal care product launch in early 2027; timeframe Jan–Apr 2027. No venue or webcast details provided.

United-Guardian has 1 upcoming scheduled event. The next event, "Personal care product launch", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the UG stock price.

Short Interest History

Last 12 Months

Short interest in United-Guardian (UG) currently stands at 8.6 thousand shares, up 14.4% from the previous reporting period, representing 0.3% of the float. Since November 2025, short interest has increased by 15.3%.

Days to Cover History

Last 12 Months

Days to cover for United-Guardian (UG) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 5.6 days.

UG Company Profile & Sector Positioning

United-Guardian (UG) operates in the Household & Personal Products industry within the broader Consumer Defensive sector and is listed on the NASDAQ.

Investors comparing UG often look at related companies in the same sector, including Grove Collaborative Holdings, Inc. (GROV), Tantech Holdings Ltd. (TANH), Big Tree Cloud Holdings Limited (DSY), Instinct Bio Technical Company Holdings Inc. (BIOT), and SkinHealth Systems Inc. (SKIN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate UG's relative position within its industry.

Frequently Asked Questions

The current stock price of United-Guardian (UG) is $7.20 in after-hours trading as of November 20, 2026.

The market cap of United-Guardian (UG) is approximately $33.1M. Learn more about what market capitalization means .

The FY2025 revenue of United-Guardian (UG) is $10.5M, from its most recent completed fiscal year.

The FY2025 net income of United-Guardian (UG) is $2.1M, from its most recent completed fiscal year.

The operating cash flow of United-Guardian (UG) is $2.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of United-Guardian (UG) is 20.0% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of United-Guardian (UG) is 21.3% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of United-Guardian (UG) is 48.8% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of United-Guardian (UG), current assets divided by current liabilities, was 7.31 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of United-Guardian (UG) is $5.1M for FY2025, its most recent completed fiscal year.

The operating income of United-Guardian (UG) is $2.2M for FY2025, its most recent completed fiscal year. Learn about operating income.

United-Guardian, Inc. is a manufacturing company that produces cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. The company organizes its activities into these four main product categories within the specialty chemical manufacturing sector.

United-Guardian operates in the "All Other Miscellaneous Chemical Product and Preparation Manufacturing" industry within the broader manufacturing sector. Its focus is on specialty chemical products used in cosmetics, pharmaceuticals, medical lubrication, and sexual wellness applications.

United-Guardian states that it operates in one business segment, with its product lines separated into four categories: cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients. These categories define the core of the company’s product offerings.

Renacidin, also referred to as Renacidin Irrigation Solution, is described by United-Guardian as its most important pharmaceutical product. The company has discussed projects to have Renacidin included on additional drug formularies, with the goal of significantly increasing its sales over time.

According to company descriptions, United-Guardian’s pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly to end-users or to contract manufacturers used by those end users. For cosmetic ingredients, the company works with distributors and marketing partners.

Ashland Specialty Ingredients, often referred to as ASI, is described by United-Guardian as its largest cosmetic distributor and a key marketing partner for cosmetic ingredients. Changes in ASI’s purchasing patterns and inventory levels, influenced by demand conditions in Asia, have been cited by United-Guardian as affecting its cosmetic ingredient sales in various periods.

United-Guardian reports research and development as a separate expense category in its financial statements and highlights R&D as central to product development. The company has noted that its R&D and microbiology functions have supported the creation of new products, including a growing line of natural cosmetic ingredients.

United-Guardian has publicly announced cash dividends over many years and has stated that it has paid a dividend for multiple consecutive years. In its dividend announcements, the company explains that its Board of Directors considers both the desire to return cash to stockholders and the need to retain earnings to fund growth initiatives, such as projects to expand markets for personal care products and Renacidin.

United-Guardian’s common stock trades on NASDAQ under the ticker symbol UG. The company references this listing in its press releases and SEC filings.

United-Guardian files reports with the U.S. Securities and Exchange Commission, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports. Recent Form 8-K filings have been used to furnish press releases about quarterly financial results and dividend declarations under items related to results of operations and Regulation FD disclosure.